Applying Emerging Evidence in mTNBC Practice

Faculty

Ricki Fairley
Patient Advocate and Breast Cancer Survivor
CEO and Co-Founder of TOUCH BBCA

Statement of Need

Triple-negative breast cancer (TNBC) carries the poorest prognosis among the major subtypes, with a propensity for visceral and central nervous system metastases and survival in the metastatic setting frequently measured in months. Its burden falls disproportionately on younger women and Black women, who may face disparities in access to high-quality care alongside significant psychological and financial challenges. New biomarker-driven first-line therapies offer real progress but greater complexity, and clinicians outside specialized centers often struggle to apply evolving evidence and expert recommendations to guideline-concordant, individualized care.

In this CE Concepts AI-powered precision learning activity, learners will make and defend the first-line decisions that now define care for metastatic TNBC. Guided by an AI clinical advisor, learners will distinguish among available first-line treatment options using current efficacy, survival, and patient-reported outcome data, and  apply PD-L1 CPS stratification, germline BRCA1/2 mutation status, and immunotherapy eligibility history to select guideline-concordant first-line therapy. An adaptive patient encounter then challenges learners to communicate biomarker findings, incorporate patient-specific preferences, and identify resources that address access barriers, while a toxicity case requires distinguishing ADC-related from immune-related adverse events to facilitate safe treatment continuity.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Distinguish between available first-line treatment options for mTNBC based on current clinical evidence, including key efficacy, survival, and patient-reported outcome data
  • Apply PD-L1 CPS stratification, germline BRCA1/2 mutation status, and immunotherapy eligibility history to select guideline-concordant first-line therapy for individuals with mTNBC
  • Distinguish ADC-related from immune-related adverse events in individuals receiving first-line ADC plus immune checkpoint inhibitor combinations for mTNBC, using clinical features, onset timing, and available diagnostic findings
  • Utilize available patient navigation resources and community oncology network partnerships to support equitable access to emerging first-line mTNBC therapies

Financial Support

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Target Audience

Medical oncologists, breast cancer specialists, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME)

Creative Educational Concepts, LLC, designates this enduring material for a maximum of  1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Council for Pharmacy Education

This application activity is approved for 1.00 contact hours (0.1 CEUs) of continuing pharmacy credit (JA0007101-0000-26-011-H01-P).

American Nurses Credentialing Center

This activity is designated for 1.00 contact hours.

American Nurses Credentialing Center with ILNA

This activity is designated for 1.00 contact hours.

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

OCN® 
Treatment

CBCN® 
Treatment

CPHON® 
Treatment

AOCNP® 
Treatment

ROCN® 
Treatment

Physician Associates (AAPA)

Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 05/19/2027. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Ricki Fairley reports no financial relationships to disclose.

The following individuals have no financial relationships to disclose: 

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Taylor Wallace, PhD (Planning Committee)
Andrea Perseghin, EdD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.

Questions about this activity?

Call us at 859-260-1717  •  info@ceconcepts.com

COP-008-111926-47

Call us at 859-260-1717  •  info@ceconcepts.com

Applying Emerging Evidence in mTNBC Practice
Activity Date: 11/16/2026